Adults

Dosage depends on indication and patient specific factors (e.g., renal function, body weight). Typically, for stroke prevention in NVAF, 60 mg once daily, or 30 mg once daily if specific clinical factors apply (e.g., CrCl 15-50 mL/min, body weight ≤60 kg, or concomitant use of specific P-gp inhibitors). For treatment of DVT/PE, 60 mg once daily after 5-10 days of initial parenteral anticoagulation, or 30 mg once daily if specific clinical factors apply. *Edysta 10 mg is a specific lower dose and would be prescribed based on physician's assessment for certain conditions or dose adjustments.*

Elderly

No specific dose adjustment for age alone, but factors common in elderly (renal impairment, low body weight) may necessitate a 30 mg dose.

Renal_impairment

For moderate to severe renal impairment (CrCl 15-50 mL/min), a reduced dose of 30 mg once daily is typically recommended. Edoxaban 10mg might be considered in very specific severe renal cases or for other specific indications if prescribed by a specialist.

Onset

Anticoagulant effect observed within 1-2 hours.

Excretion

Primarily excreted unchanged in urine (50%) and feces (40%).

Half life

Approximately 10-14 hours.

Absorption

Rapidly absorbed; peak plasma concentrations reached in 1-2 hours.

Metabolism

Minimal metabolism (less than 10%) by hydrolysis and conjugation. CYP3A4-mediated metabolism is negligible.

NSAIDs (Nonsteroidal Anti-inflammatory Drugs)

Increased risk of bleeding, especially gastrointestinal bleeding. Use with caution.

P-gp Inducers (e.g., Rifampicin, Phenytoin, Carbamazepine, St. John's Wort)

Decreased Edoxaban exposure; avoid concomitant use if possible or monitor for efficacy.

P-gp Inhibitors (e.g., Cyclosporine, Dronedarone, Erythromycin, Ketoconazole)

Increased Edoxaban exposure; dose reduction (e.g., from 60mg to 30mg) may be required for some indications.

Other Anticoagulants/Antiplatelet agents (e.g., Warfarin, Heparin, Aspirin, Clopidogrel)

Increased risk of bleeding. Concomitant use generally not recommended, except for specific clinical situations under close monitoring.